Carol Anne Ogden
About Carol Anne Ogden
Carol Anne Ogden serves as the Executive Director of Clinical and Translational Sciences at Sana Biotechnology, Inc., where she leads efforts in developing innovative therapies for Type 1 Diabetes. With over two decades of experience in the biopharmaceutical industry, she has held various roles in translational medicine and has expertise in immunology and disease biology.
Current Role at Sana Biotechnology
Carol Anne Ogden serves as the Executive Director of Clinical and Translational Sciences at Sana Biotechnology, Inc. since 2021. In this role, she leads translational efforts for innovative therapies, including SC451, a hypoimmune iPSC-derived islet cell replacement therapy aimed at treating Type 1 Diabetes. Her work focuses on advancing clinical applications and ensuring the successful transition of research findings into therapeutic solutions.
Previous Experience in the Biopharmaceutical Industry
Prior to her current position, Ogden held various roles in the biopharmaceutical industry. She worked at GSK as an Investigator in Immuno-Inflammation from 2005 to 2010, and later served as Principal Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2010 to 2014. She also held positions at Seagen, OncoResponse Inc., and NodThera Limited, contributing to translational medicine and immuno-oncology research.
Educational Background and Expertise
Ogden earned her Bachelor of Science in Microbiology from Colorado State University, followed by a PhD in Experimental Pathology from the University of Colorado. She has extensive expertise in various disease areas, including immuno-oncology, autoimmunity, and inflammatory diseases. Her academic training laid the foundation for her two decades of experience in the biopharmaceutical sector, particularly in macrophage and innate immune biology.
Research Contributions and Projects
Throughout her career, Ogden has contributed to significant research projects, including providing translational immunology support for SC291, an allogeneic hypoimmune CAR T cell therapy. Her work spans multiple therapeutic areas, demonstrating her ability to lead and innovate in the development of advanced biopharmaceutical therapies.
Postdoctoral Research Experience
Ogden completed her postdoctoral research at The University of Edinburgh and the University of Washington. At the Centre for Inflammation Research, she focused on inflammation mechanisms, while at the Keith Elkon Lab in the Division of Rheumatology, she furthered her understanding of immune responses. These experiences contributed to her expertise in translational sciences.